Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Esperion Therapeutics Inc
ESPR | US
3.14
USD0.01
0.32%
ESPR | US
About Esperion Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
3.14
Open
3.13
High
3.14
Low
3.13
Esperion Therapeutics Inc. a pharmaceutical company develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral small molecule PCSK9 inhibitor program. Esperion Therapeutics Inc. was incorporated in 2008 and is headquartered in Ann Arbor Michigan.
View LessESPR | US
Risk
4.6
Sharpe
2.81
Luna's Score
55/100
Recommendation
Hold
Luna says (ESPR | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
2.9%1 month
4.6%3 months
129.0%6 months
99.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
1.64
Price to book
98.42
Debt to equity
-1.62
Debt to assets
1.58
Ent. to EBITDA
-3.86
Ent. to rev.
1.78
PEG
-4.78
Other Fundamentals
EBITDA
4.99M
MarketCap
637.29M
MarketCap(USD)
637.29M
Div. yield
-
Op. margin
3.49
Erngs. growth
-
Rev. growth
186.30
Ret. on equity
-260.79
Short ratio
12.69
Short perc.
19.14
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.02
Range1M
0.08
Range3M
1.47
Volumes: Market Activity
Rel. volume
1.05
Price X volume
43.36M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.86 | - | Cheaper |
| Ent. to Revenue | 1.78 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 98.42 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 128.96 | - | Riskier |
| Debt to Equity | -1.62 | -1.23 | Cheaper |
| Debt to Assets | 1.58 | 0.25 | Expensive |
| Market Cap | 637.29M | - | Emerging |
